Reuters logo
BRIEF-Biocartis Group: study using Biocartis' liquid biopsy BRAF assay shows new option for retreatment of melanoma patients
March 9, 2017 / 6:39 AM / 7 months ago

BRIEF-Biocartis Group: study using Biocartis' liquid biopsy BRAF assay shows new option for retreatment of melanoma patients

March 9 (Reuters) - Biocartis Group Nv:

* Reg-Biocartis Group NV: study using Biocartis’ liquid biopsy BRAF assay shows new option for retreatment of melanoma patients

* Study and editorial ‘A second chance for success with BRAF and MEK inhibitors in melanoma’ published in renowned clinical journal Lancet Oncology Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below